Table 4.
(A) Comparison of fasting blood glucose (FBG) between the treatment groups during the experimental period of gentamycin-induced nephrotoxic rats.
| Treatment groups | Day-7 | Day-14 | Day-21 | Day-28 | ||
|---|---|---|---|---|---|---|
| STD | 11.26 (±0.37) | 10.56 (±0.46) | 10.66 (±0.34) | 10.94 (±0.50) | ||
| CON | 7.28 (±0.24) * | 7.44 (±0.30) * | 7.42 (±0.25) * | 7.72 (±0.38) * | ||
| STV | 9.96 (±0.69) | 7.84 (±0.29) * | 7.78 (±0.15) * | 8.80 (±0.53) | ||
| AML | 9.72 (±0.31) * | 8.40 (±0.37) * | 8.84 (±0.54) * | 8.70 (±0.39) * | ||
| LOS | 8.58 (±0.38) * | 8.56 (±0.35) * | 8.54 (±0.26) * | 8.56 (±0.19) * | ||
| VAS | 9.54 (±0.28) * | 8.90 (±0.56) * | 9.12 (±0.62) * | 9.22 (±0.38) * | ||
| (B) Repeated measures ANOVA followed by pairwise comparison for fasting blood glucose (FBG) between the treatment groups during the experimental period of gentamycin-induced nephrotoxic rats | ||||||
|---|---|---|---|---|---|---|
| WEEK | WEEK | Mean Difference | Std. Error | Sig. | 95% Confidence Interval for Difference | |
| Lower Bound | Upper Bound | |||||
| 1 | 2 | .753* | .174 | .001 | .265 | 1.240 |
| 3 | .700* | .195 | .006 | .153 | 1.247 | |
| 4 | .308 | .147 | .256 | −0.102 | .718 | |
| 2 | 1 | −0.753* | .174 | .001 | −1.240 | −0.265 |
| 3 | −0.053 | .104 | 1.000 | −0.344 | .239 | |
| 4 | −0.444* | .147 | .027 | −0.854 | −0.035 | |
| 3 | 1 | −0.700* | .195 | .006 | −1.247 | −0.153 |
| 2 | .053 | .104 | 1.000 | −0.239 | .344 | |
| 4 | −0.392 | .154 | .094 | −0.823 | .039 | |
| 4 | 1 | −0.308 | .147 | .256 | −0.718 | .102 |
| 2 | .444* | .147 | .027 | .035 | .854 | |
| 3 | .392 | .154 | .094 | −0.039 | .823 | |